<DOC>
	<DOCNO>NCT02588625</DOCNO>
	<brief_summary>This two part study . The purpose Part A determine BMS-986020 effective treatment diffuse cutaneous systemic sclerosis use one dose BMS-986020 . The purpose Part B determine BMS-986020 effective treatment diffuse cutaneous systemic sclerosis use two different dos BMS-986020 .</brief_summary>
	<brief_title>A Double-Blinded Study Evaluate Safety , Tolerability , Efficacy BMS-986020 Versus Placebo Diffuse Cutaneous Systemic Sclerosis ( dcSSc )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Diagnosis diffuse cutaneous systemic sclerosis 60 month less Men woman â‰¥ 18 year age Ability comply birth control requirement Certain immunosuppressive agent permit Limited cutaneous systemic sclerosis sine scleroderma Active ulcer finger Pulmonary arterial hypertension Any gastrointestinal surgery may impact absorption study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>